Cargando…

Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases

Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data. The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n = 101) were i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yi-Qing, Li, He-Jun, Chen, Ling, Lin, Shun-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606114/
https://www.ncbi.nlm.nih.gov/pubmed/36289319
http://dx.doi.org/10.1038/s41598-022-22839-0
_version_ 1784818228649787392
author Zheng, Yi-Qing
Li, He-Jun
Chen, Ling
Lin, Shun-Ping
author_facet Zheng, Yi-Qing
Li, He-Jun
Chen, Ling
Lin, Shun-Ping
author_sort Zheng, Yi-Qing
collection PubMed
description Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data. The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n = 101) were included in this study. All patients received 2 doses of inactivated COVID-19 vaccine. Serum anti-S1/RBD protein IgG was detected 2–16 weeks after the second vaccination. Seropositivity was defined as IgG ≥ 1.00 bound antibody unit S/CO. Immunogenicity of inactivated COVID-19 vaccine was assessed by seropositivity rate and the levels of serum IgG antibody against anti-S1/RBD protein, compared with the general population (n = 46). There was no difference by statistical significance in the seropositivity rate between patients with AIIRD (82.2%) and SLE (86.1%) and the control group (93.5%), p > 0.05. The level of anti-S1/RBD protein IgG antibodies in patients with AIIRD (median [IQR], 8.8 [2.2–17.3]) and SLE (median [IQR], 9.6 [2.4–20.4]) was comparable to that in the control group (median [IQR], 7.2 [3.1–14.2]), p > 0.05. Patients treated with glucocorticoids(GCs) (median dose, [IQR]: 2.5 mg/day [IQR 2.5–5.0]) or hydroxychloroquine(HCQ) or GCs + HCQ without other immunomodulatory medications, had an appropriate immunogenic response(88.1%) with high levels of anti-S1/RBD protein IgG(median [IQR], 12.1 [6.5–20.4]). Neither of patients treated with rituximab had positive serum antibodies, which was statistically significant, compared with the control group (p < 0.01). Compared with the control group, methotrexate(MTX) and iguratimod(IGU) was significantly reduced the level of anti-S1/RBD protein IgG antibodies. Inactivated COVID-19 vaccine had appropriate immunogenicity in patients with AIIRD. Immunogenicity of inactivated COVID-19 vaccine was severely impaired by rituximab, and also suppressed by MTX and IGU, while low doses of GC and HCQ had negligible effect.
format Online
Article
Text
id pubmed-9606114
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96061142022-10-28 Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases Zheng, Yi-Qing Li, He-Jun Chen, Ling Lin, Shun-Ping Sci Rep Article Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data. The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n = 101) were included in this study. All patients received 2 doses of inactivated COVID-19 vaccine. Serum anti-S1/RBD protein IgG was detected 2–16 weeks after the second vaccination. Seropositivity was defined as IgG ≥ 1.00 bound antibody unit S/CO. Immunogenicity of inactivated COVID-19 vaccine was assessed by seropositivity rate and the levels of serum IgG antibody against anti-S1/RBD protein, compared with the general population (n = 46). There was no difference by statistical significance in the seropositivity rate between patients with AIIRD (82.2%) and SLE (86.1%) and the control group (93.5%), p > 0.05. The level of anti-S1/RBD protein IgG antibodies in patients with AIIRD (median [IQR], 8.8 [2.2–17.3]) and SLE (median [IQR], 9.6 [2.4–20.4]) was comparable to that in the control group (median [IQR], 7.2 [3.1–14.2]), p > 0.05. Patients treated with glucocorticoids(GCs) (median dose, [IQR]: 2.5 mg/day [IQR 2.5–5.0]) or hydroxychloroquine(HCQ) or GCs + HCQ without other immunomodulatory medications, had an appropriate immunogenic response(88.1%) with high levels of anti-S1/RBD protein IgG(median [IQR], 12.1 [6.5–20.4]). Neither of patients treated with rituximab had positive serum antibodies, which was statistically significant, compared with the control group (p < 0.01). Compared with the control group, methotrexate(MTX) and iguratimod(IGU) was significantly reduced the level of anti-S1/RBD protein IgG antibodies. Inactivated COVID-19 vaccine had appropriate immunogenicity in patients with AIIRD. Immunogenicity of inactivated COVID-19 vaccine was severely impaired by rituximab, and also suppressed by MTX and IGU, while low doses of GC and HCQ had negligible effect. Nature Publishing Group UK 2022-10-26 /pmc/articles/PMC9606114/ /pubmed/36289319 http://dx.doi.org/10.1038/s41598-022-22839-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zheng, Yi-Qing
Li, He-Jun
Chen, Ling
Lin, Shun-Ping
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
title Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
title_full Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
title_fullStr Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
title_full_unstemmed Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
title_short Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
title_sort immunogenicity of inactivated covid-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606114/
https://www.ncbi.nlm.nih.gov/pubmed/36289319
http://dx.doi.org/10.1038/s41598-022-22839-0
work_keys_str_mv AT zhengyiqing immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases
AT lihejun immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases
AT chenling immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases
AT linshunping immunogenicityofinactivatedcovid19vaccineinpatientswithautoimmuneinflammatoryrheumaticdiseases